Ten years ago, the first studies comparing the results of adult versus pediatric protocols in adolescents with acute lymphoblastic leukemia (ALL) clearly showed that differences in ALL genetics and treatment tolerance could not be the only reasons for the worse outcome observed in adults with this disease as compared to children. It became evident that intensified pediatric chemotherapy regimens could be associated with better response rates and longer survival in adults as well. During the last decade, the use of pediatric-like or pediatric-inspired protocols in adults allowed markedly improving the outcome of young adult patients aged up from 40 years to 60 years, confirming this initial observation. Administration of pediatric-like therapy in adults is now associated with estimated 5-year overall survival comprised between 60 % and 70 %. In this new context, the risk factors and the place of stem cell transplantation need to be reassessed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11899-014-0210-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bridging the age gap: a review of molecularly informed treatments for glioma in adolescents and young adults.
Front Oncol
September 2023
Translational Brain Tumor Research Group, Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
Gliomas are the most common primary central nervous system (CNS) tumors and a major cause of cancer-related mortality in children (age <15 years), adolescents and young adults (AYA, ages 15-39 years), and adults (age >39 years). Molecular pathology has helped enhance the characterization of these tumors, revealing a heterogeneous and ever more complex group of malignancies. Recent molecular analyses have led to an increased appreciation of common genomic alterations prevalent across all ages.
View Article and Find Full Text PDFComparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis.
Leuk Res
July 2023
Department of Adult Hematology and Stem Cell Transplantation, Princess Noorah Oncology Center, Ministry of the National Guard Health Affairs, Jeddah, Saudi Arabia; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Saudi Arabia; King Abdullah International Medical Research Center, Saudi Arabia; Saudi Society of Blood and Bone Marrow Transplantation (SSBMT), Saudi Arabia.
Background: The outcomes of Pediatric acute lymphoblastic leukemia (ALL) have improved dramatically whereas outcomes for ALL amongst adolescents and young adults (AYA) have lagged behind. The introduction of pediatric-like regimens to manage adult ALL has shown promising outcomes across several analyses.
Materials And Methods: In this analysis, we aimed to retrospectively compare the differences in outcomes among patients aged 14-40 years with Philadelphia-negative ALL treated with a Hyper-CVAD protocol versus a modified pediatric protocol.
Spatial aerosol deposition correlated to anatomic feature development in 6-year-old upper airway computational models.
Comput Biol Med
October 2022
Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE, USA. Electronic address:
The upper airways of children undergo developmental changes around age 6, yielding differences between adult and pediatric anatomies. These differences include the cricoid ring area shape, the location of narrowest constriction, and the angle of the epiglottis, all of which are expected to alter local fluid dynamic profiles and subsequent upper airway deposition and downstream aerosol delivery of inhaled therapeutics. In this work, we quantify "pediatric"-like and "adult"-like geometric and fluid dynamic features of two computed tomography (CT)-scan derived models of 6-year-old upper airways in healthy subjects and compare to an idealized model.
View Article and Find Full Text PDFPharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature.
Expert Opin Pharmacother
April 2022
Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Introduction: T-cell acute lymphoblastic leukemia (T-ALL) is a rare but potentially life-threatening heterogeneous hematologic malignancy that requires prompt diagnosis and treatment by hematologists. So far, therapeutic advances have been achieved in the management of this disease mainly by adopting pediatric-like regimens, and cure rates are significantly worse than in childhood. In T-ALL, less than 70% of adults achieve long-term survival.
View Article and Find Full Text PDF[B cell acute lymphoblastic leukemia therapy: an up to date overview].
Rinsho Ketsueki
September 2021
Division of Cellular and Genetic Sciences, Nagoya University Graduate School of Medicine.
It is over two decades since the first retrospective analysis indicated the superiority of pediatric-like therapy for adolescent and young adult (AYA) patients in 2000. To date, many prospective studies confirmed the efficacy and safety of pediatric-like therapy for AYA and older adult ALL, while therapy for pediatric ALL also made progress by innovating a new technology such as stratification of therapy by minimal residual disease (MRD). Furthermore, it is expected that further improvements will be achieved by applying newly approved anti-cancer drugs such as inotuzumab ozogamicin and blinatumomab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!